Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects

Clin Exp Dermatol. 2021 Apr;46(3):550-552. doi: 10.1111/ced.14426. Epub 2020 Sep 14.

Authors

L J Albrecht¹, M Moelleken¹, J Dissemond¹

Affiliation

¹ Department of Dermatology, Venerology and Allergology, University of Essen, Germany.

PMID: 32810347
DOI: 10.1111/ced.14426

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab / adverse effects*
Herpes Zoster / diagnosis*
Herpes Zoster / drug therapy
Humans
Immunocompromised Host*
Immunosuppressive Agents / adverse effects*
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / immunology*
Risk Factors
Time Factors
Virus Activation

Substances

Immunosuppressive Agents
Alemtuzumab